全文获取类型
收费全文 | 10885篇 |
免费 | 1299篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 180篇 |
儿科学 | 163篇 |
妇产科学 | 183篇 |
基础医学 | 576篇 |
口腔科学 | 6743篇 |
临床医学 | 561篇 |
内科学 | 932篇 |
皮肤病学 | 266篇 |
神经病学 | 330篇 |
特种医学 | 115篇 |
外科学 | 831篇 |
综合类 | 66篇 |
一般理论 | 7篇 |
预防医学 | 414篇 |
眼科学 | 85篇 |
药学 | 336篇 |
中国医学 | 48篇 |
肿瘤学 | 394篇 |
出版年
2024年 | 35篇 |
2023年 | 441篇 |
2022年 | 208篇 |
2021年 | 332篇 |
2020年 | 301篇 |
2019年 | 322篇 |
2018年 | 556篇 |
2017年 | 532篇 |
2016年 | 565篇 |
2015年 | 647篇 |
2014年 | 703篇 |
2013年 | 719篇 |
2012年 | 623篇 |
2011年 | 594篇 |
2010年 | 499篇 |
2009年 | 657篇 |
2008年 | 405篇 |
2007年 | 336篇 |
2006年 | 312篇 |
2005年 | 230篇 |
2004年 | 208篇 |
2003年 | 236篇 |
2002年 | 196篇 |
2001年 | 186篇 |
2000年 | 158篇 |
1999年 | 177篇 |
1998年 | 236篇 |
1997年 | 206篇 |
1996年 | 197篇 |
1995年 | 177篇 |
1994年 | 170篇 |
1993年 | 130篇 |
1992年 | 140篇 |
1991年 | 85篇 |
1990年 | 92篇 |
1989年 | 58篇 |
1988年 | 84篇 |
1987年 | 78篇 |
1986年 | 38篇 |
1985年 | 60篇 |
1984年 | 59篇 |
1983年 | 57篇 |
1982年 | 51篇 |
1981年 | 32篇 |
1978年 | 11篇 |
1977年 | 10篇 |
1976年 | 11篇 |
1975年 | 15篇 |
1974年 | 12篇 |
1972年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Pablo Galindo-Moreno DDS PhD Natividad Martín-Morales BS Allinson Olaechea DDS MS Pedro Hernández-Cortes MD PhD Cristobal Verdugo-Escamilla BDC MSc PhD Francisca Martinez-Ruiz BS PhD Ana Belen Carrillo-Galvez PhD Francisco O'Valle MD PhD Miguel Padial-Molina DDS PhD 《Clinical implant dentistry and related research》2023,25(2):370-380
993.
994.
995.
996.
997.
Warda Jamshaid Maryam Jamshaid Chris Coulson Neil Sharma Jameel Muzaffar Hannah Nieto 《Clinical otolaryngology》2023,48(4):527-539
Background
Intraoperative and postoperative blood loss is a major risk in head and neck (H&N) surgery. Recently the use of tranexamic acid (TXA) has been investigated by multiple studies for reducing intraoperative and postoperative bleeding, however reported results are variable.Objectives
To determine the safety and efficacy of TXA use in H&N surgery.Methods
Systematic review of MEDLINE, EMBASE, CINAHL, Cochrane Library, PubMed, ClinicalKey, and Clinicaltrials.gov according to the PRISMA guidelines. Studies were included if they reported on intraoperative bleeding, volume or duration of postoperative drain or return to theatre rate for postoperative haemorrhage in adult populations following use of TXA. Risk of bias assessment with Cochrane Risk of Bias (RoB2) tool for randomised controlled trials and Newcastle–Ottawa Scale tool for non-randomised studies.Results
Sixteen studies were identified (114 407 patients). Eight studies evaluated TXA in major H&N surgery and eight studies in tonsillectomy. Primary outcomes were reduction in intraoperative or postoperative bleeding. Secondary outcomes included the duration of postoperative drain placement and return to theatre rate. No adverse events were reported in any patients. TXA is effective in reducing intraoperative blood loss in tonsillectomy. However, the effect on posttonsillectomy haemorrhage was unclear. Insufficient evidence exists of benefit of TXA on intraoperative bleeding in major H&N procedures. Postoperative drainage volumes were significantly reduced in most major H&N studies. The duration of drain placement and risk of blood transfusion was unchanged in most cases.Conclusion
TXA use is safe in H&N patients. Whilst sufficient evidence exists to support the use of TXA in tonsillectomy, insufficient evidence exists to recommend use in major H&N surgery. 相似文献998.
Mohammad T. Yousafzai Maryam Alavi Heather Valerio Behzad Hajarizadeh Jason Grebely Gregory J. Dore 《Journal of viral hepatitis》2023,30(3):250-261
The hepatitis C virus (HCV) care cascade characterization is important for monitoring progress towards HCV elimination. This study evaluated HCV care cascade and factors associated with treatment during pre-DAA (2011–2012 and 2013–2015) and DAA (2016–2018) eras in New South Wales (NSW), Australia. We conducted a cohort study of people with an HCV notification (1993 to 2017) through end 2018, linked to administrative datasets, including HCV treatment and non-hospital services. Those aged <18 years, died within first 6 months of study period or notification, and who had successful HCV treatment in period before were excluded. Sex-specific spontaneous viral clearance was incorporated to estimate treatment-eligible population. The study population in each period were cumulative and brought forward from one period to the next. Among 115,667 people with HCV notification, 87,063 fulfilled eligibility criteria. During 2011 to 2012, 2013 to 2015, and 2016 to 2018, cumulative HCV notifications were 71,677, 77,969, and 80,017; 52,016, 56,793, and 57,467 were eligible for treatment; 29%, 48%, and 64% confirmed HCV RNA positive; and 0.6%, 5%, and 38% initiated HCV treatment, respectively. Birth cohort 1945 to 1964 (vs. ≥1965), males, non-Aboriginal ethnicity, regional/rural area of residence, and HCV/HIV co-infection were associated with higher treatment uptake. Incarceration and drug dependence were associated with higher treatment uptake during the DAA era. In Australia, many marginalized populations including those incarcerated and those with drug dependence have equitable treatment uptake in the DAA era. Targeted strategies are required to enhance treatment uptake for females and Aboriginal populations. 相似文献
999.
Mohammad Nekooeian Shahrokh Ezzatzadegan Jahromi Fatemeh Masjedi Maryam Sohooli Ramin Shekouhi Alireza Moaref 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2023,27(4):760-770
1000.
Mohammad Ali Nilforoushzadeh MD Maryam Golparvaran PhD Mir Saeed Yekaninejad PhD 《Journal of Cosmetic Dermatology》2023,22(8):2283-2287